ProShare Advisors LLC Decreases Holdings in Illumina, Inc. (NASDAQ:ILMN)

ProShare Advisors LLC reduced its position in Illumina, Inc. (NASDAQ:ILMN) by 17.8% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 154,422 shares of the life sciences company’s stock after selling 33,353 shares during the period. ProShare Advisors LLC owned about 0.10% of Illumina worth $16,119,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Envestnet Portfolio Solutions Inc. increased its position in shares of Illumina by 426.0% in the first quarter. Envestnet Portfolio Solutions Inc. now owns 15,460 shares of the life sciences company’s stock valued at $2,123,000 after buying an additional 12,521 shares in the last quarter. Findlay Park Partners LLP purchased a new position in Illumina during the 1st quarter valued at about $100,120,000. Jupiter Asset Management Ltd. acquired a new position in Illumina during the first quarter worth about $4,527,000. US Bancorp DE lifted its holdings in shares of Illumina by 33.9% in the first quarter. US Bancorp DE now owns 31,600 shares of the life sciences company’s stock valued at $4,339,000 after purchasing an additional 8,001 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its position in shares of Illumina by 41.4% in the first quarter. BNP Paribas Financial Markets now owns 390,035 shares of the life sciences company’s stock valued at $53,560,000 after purchasing an additional 114,263 shares during the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Trading Down 0.8 %

NASDAQ ILMN opened at $130.10 on Tuesday. The stock has a market cap of $20.72 billion, a P/E ratio of -15.96 and a beta of 1.15. The company’s fifty day simple moving average is $125.52 and its 200-day simple moving average is $120.42. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 1.04. Illumina, Inc. has a 52 week low of $89.00 and a 52 week high of $148.19.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, August 6th. The life sciences company reported $0.36 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.24. The firm had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.09 billion. Illumina had a negative net margin of 68.73% and a positive return on equity of 3.08%. The firm’s revenue was down 5.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.32 EPS. Equities research analysts predict that Illumina, Inc. will post 3.62 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ILMN has been the topic of a number of analyst reports. Robert W. Baird increased their target price on Illumina from $119.00 to $124.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Stephens reiterated an “overweight” rating and set a $170.00 price objective on shares of Illumina in a research report on Wednesday, July 10th. StockNews.com began coverage on shares of Illumina in a research note on Thursday, August 29th. They issued a “buy” rating for the company. Piper Sandler decreased their price target on shares of Illumina from $200.00 to $195.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 13th. Finally, Scotiabank cut their price objective on shares of Illumina from $176.00 to $164.00 and set a “sector outperform” rating for the company in a research report on Thursday, August 15th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Illumina presently has an average rating of “Moderate Buy” and a consensus target price of $151.05.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.